MedInvent Receives CE Mark for NasoNeb II Nasal Nebulizer

Medical Device Company Receives ISO and CMDCAS Certification; Signs First European Distributor

Print
| Source: MedInvent
photo-release

MedInvent NasoNeb II Nasal Nebulizer

MedInvent NasoNeb II Nasal Nebulizer

MedInvent NasoNeb II Nasal Nebulizer

MedInvent

CLEVELAND, March 14, 2017 (GLOBE NEWSWIRE) -- MedInvent, LLC, is pleased to announce CE Marking of its patented intranasal delivery device, the NasoNeb II Nasal Nebulizer, manufactured, marketed and sold in the United States since 2009. MedInvent is also pleased to announce its first EU distribution contract with Vedise Hospital in Rome, to market the NasoNeb System in Italy, San Marino and Vatican City. Vedise Hospital has marketed ENT products for over 20 years, serving Otolaryngologists in Italy. 

In addition, MedInvent has obtained ISO 13485 and CMDCAS certification. These certifications, together with CE Marking, enable MedInvent to expand the market for the NasoNeb II Nasal Nebulizer to the member countries of the European Union and to seek regulatory approval in countries around the world.

The NasoNeb System has been the delivery device of choice in multiple peer-reviewed trials, where it has demonstrated positive outcomes in chronic sinusitis and allergic rhinitis patients. The System is a controlled intranasal delivery system whereby its unique combination of droplet size, airflow, and fluid volume allows delivery solely to the nasal and paranasal sinus cavities. In addition, the NasoNeb offers broad intranasal drug deposition, high intranasal drug retention, and no pulmonary deposition. Other delivery devices reach a limited area of the nasal cavity, deliver a weak solution, or deliver a portion of the medication to the lungs, which can cause unwanted side effects.

“We look forward to working with European physicians treating patients who suffer with sinus conditions,” said William Flickinger, MedInvent Managing Partner. “In particular, for those people who have not responded to therapy in the way their physicians would have expected, despite their physician’s best efforts, the NasoNeb System represents a promising new delivery method to ensure that a high concentration of medication is delivered throughout the nasal and paranasal sinus cavities.”

In the US, the NasoNeb System is available through the member pharmacies of the NasoNeb Pharmacy Network. Distributor inquiries are welcome.

A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3d1597c6-ad83-4837-b414-a13ab495b38b

About MedInvent, LLC
MedInvent, LLC, is a privately-held limited liability corporation with operations in Cleveland, OH. MedInvent develops and markets the NasoNeb Family of drug delivery systems for the topical delivery of medication to the nasal and paranasal sinus cavities. MedInvent is a non-diluted company seeking to raise its series A round to fund European Union launch, complete development of next generation products, and undertake clinical trials.

For more information, please visit the MedInvent, website at www.nasoneb.com. You can also follow us on Facebook.

Contact
William Flickinger, Managing Partner
1-330-247-0921